Philip Gould
United Kingdom, London
Founder, OVO Manufacturing


Our business centres on the identification of a naturally occurring biological contaminant that significantly reduces viral vaccine yields (up to 1000-fold).

We have developed a technology platform that can identify and reduce the impact of this contaminant leading to significant improvements in yields and profits without impacting regulatory compliance.

Processing. Please wait.